AZBio
10/13/20172017 Fast Lane Honoree Avery Therapeutics
More than 26 million people worldwide suffer from heart failure and the number of cases is increasing at more than 13% per year. In the US, heart failure is the number one cause of hospital readmissions in patients over 65 and results in over $39 billion in treatment costs annually. The progression of heart failure results in a 50% mortality rate within 5 years of diagnosis. But what if it didn’t have to be like this? That is a question being addressed by the team at Avery Therapeutics, Inc. The startup company is based on the application of technology invented at the University of Arizona College of Medicine-Tucson and the Southern Arizona VA. In 2017, Avery Therapeutics licensed the beating heart graft technology from the University of Arizona. Pre-clinical studies have already shown that the technology, called MyCardia™, improves heart function.
AZBio
05/11/2015Clinical Trials in Arizona
Joan Koerber-Walker, President & CEO of AZBio provides a look at how Arizona stacks up when it comes to clinical trials.
AZBio
05/18/2016Reshaping the Patient Experience (Panel)
Moderated by Jude LaCava, Co-founder, Dorothy Foundation;
Panelists: -Eric Greenman, MD, Founder
and Chief Medical Officer, iTel Companies; Marie
Wesslehoft, President & Co-founder, MSDx; Neel
Mehta, Co-founder and Chief Strategy Officer, EpiFinder Inc.
AZBio
10/13/2017Bard Peripheral Vascular - 2017 Arizona Bioscience Company of the Year
Bard Peripheral Vascular specializes in the development of surgical and interventional devices for the treatment of diseases affecting the peripheral vascular system, which consists of veins and arteries in the arms, hands, legs, and feet. The peripheral arteries supply oxygenated blood to the body, and the peripheral veins lead deoxygenated blood from the capillaries in the extremities back to the heart.
AZBio
05/16/2015Clinical Trials in Arizona - CBR
Cord Blood Registry® (CBR®) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today Presenter: CeciliaFairley, Clincial Specialist at Cord Blood Registry
AZBio
10/13/2017Arizona's Bioindustry is Blooming
Photos Courtesy of : ASU Biodesign Institute, Banner Health, Barrow Neurological Institute, Northern Arizona University, TGen, The University of Arizona, UA College of Medicine Phoenix. All rights reserved